依达拉奉注射液治疗外伤性脑梗死的疗效与安全性

Effects and Safety of Edaravone Injection in the Treatment of Traumatic Cerebral Infarction

目的:探讨依达拉奉治疗外伤性脑梗死(TCI)的临床疗效和安全性。方法:60例外伤性脑梗死患者随机分为A、B2组各30例,2组基础治疗相同,A组同时静脉滴注依达拉奉注射液30mg及生理盐水100ml,每日2次;B组静脉滴注胞二磷胆碱注射液0.5g及生理盐水100ml,每日2次,均治疗14d。治疗前和治疗14、28d时分别以格拉斯哥昏迷量表(GCS)评定脑损伤严重程度,神经功能缺损(ESS)积分率评定临床疗效。结果:治疗14和28d时分别进行CSS评定,总有效率A组明显高于B组(53%、77%与27%、47%,P<0.05和0.01);GCS评分,A组明显高于B组(11±1、13±1与9±1、11±1,P<0.05和0.01);2组的不良反应率比较差异无显著性意义(13%与10%)。结论:依达拉奉治疗外伤性脑梗死可显著提高临床疗效,促进神经功能康复,且治疗过程安全。

Objective：To inquire the clinical effects and safety of edaravone injection in the treatment of traumatic cerebral infarction （TCI）. Methods：Sixty patients with TCI were chosen and divided into treatment group （30 cases） and control group （30 cases） randomly. The patients in treatment group received edaravone injection （30 mg） dissolved in sodium chloride injection （100 mL）, i.v. , drip, twice a day, for 14 days, and those in control group received citicoline injection （0.5 g） dissolved in sodium chloride injection （100 mL）, i. v. , drip, twice a day, for 14 days. The basic treatment was same in two groups. Before and at 14th and 28th day after treatment, the neurological deficits and the brain injuries degree were evaluated using European Stroke Scale （ESS） and Glasgow Coma Score （GCS）. Results： At 14th and 28th day after treatment, the total effective rate of ESS in treatment group was 53% and 77% respectively, and that of ESS in control group were 27% and 47% respectively; the GCS scores in treatment group were 11±1 and 13±1 respectively, and those in control group were 9±1 and 11±1 respectively. At the same time points, there was statistically significant difference between two groups （P〈0. 05 or 〈0.01）. The incidence of adverse reaction in treatment and control groups was 13 % and 10% respectively with the difference being not significant. Conclusion：Edaravone injection was effective and safe in the treatment of TCI.